Ghana's Naomi Oyoe Ohene Oti Wins Aster Guardians Global Nursing Award 2025 Worth USD 250,000
Article content
DUBAI, United Arab Emirates — Nurse Naomi Ohene Oti from Ghana has been named the winner of the Aster Guardians Global Nursing Award 2025, selected from 100,000 applications from 199 countries. An Oncology Nurse Specialist and Head of Nursing at the National Radiotherapy Oncology and Nuclear Medicine Centre, Korle-Bu Teaching Hospital, she was recognised with USD 250,000 at a prestigious ceremony held in Dubai, UAE.
Article content
Article content
The Aster Guardians Global Nursing Award was launched in 2021 to recognize the invaluable role of nurses in healthcare. The award was presented by His Excellency Sheikh Nahyan bin Mabarak Al Nahyan, Minister of Tolerance and Coexistence, UAE in presence of Dr Azad Moopen and Alisha Moopen. During this year's ceremony, Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, shared a special message applauding Aster's effort in putting a spotlight on the contributions of nurses worldwide.
Article content
Nurse Naomi Ohene Oti said, 'For over two decades, I've witnessed the inequities in cancer care firsthand and dedicated myself to closing these gaps through training, outreach, and system-level change. This award will help amplify our impact – scaling training, building faculty, and inspiring the next generation of oncology nurses across Africa.'
Article content
Dr. Azad Moopen, Founder Chaiman, Aster DM Healthcare stated, 'Nurse Naomi Ohene Oti has redefined what it means to be a nurse – not just as a caregiver but as an innovator, leader, and changemaker. Her contributions uplift not only patients but the entire healthcare ecosystem, setting a gold standard for others to follow.
Article content
Alisha Moopen, Managing Director and Group CEO, Aster DM Healthcare added, 'Naomi Ohene Oti's story is a powerful reminder of the quiet heroism that unfolds every day in hospitals, clinics, and communities across the world. We are incredibly proud to shine a global spotlight on her work, and through her, honour the millions of nurses who keep healthcare systems running and humanity thriving.'
Article content
Founded in 1987 by Dr. Azad Moopen, Aster DM Healthcare is a leading integrated healthcare provider, with a strong presence across seven countries. Aster is committed to the vision of providing accessible and high-quality healthcare, from primary to quaternary services, with its promise of 'We will treat you well'.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla. , June 4, 2025 /CNW/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina -based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The acquisition represents a key step in Continuity's strategy to become a leader in device targeted therapeutics for intractable solid tumors. Founded by leading scientists and clinicians, Focal Medical has developed a proprietary platform that delivers chemotherapy directly to tumors using iontophoresis —this minimally-invasive technique utilizes a mild electrical current to drive therapeutic compounds into targeted tissues. This method enhances local drug concentration while minimizing systemic toxicity, a critical need in the treatment of pancreatic and other solid-tissue cancers. Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. Phase 1b clinical trials are expected to begin later this year. "This is a transformative milestone for Continuity Biosciences," said Ramakrishna Venugopalan , PhD, MBA, Chief Executive Officer of Continuity Biosciences. "Focal Medical's approach to localized drug delivery aligns perfectly with our vision to improve bioavailability, reduce systemic exposure, and deliver better outcomes for patients. We are thrilled to bring this promising platform into our portfolio and into the clinic." Through the acquisition, Continuity Biosciences obtains Focal Medical's entire patent estate, iontophoresis technology platform and specialized equipment, scientific know-how, and licensing agreements with the University of North Carolina at Chapel Hill . In addition, key scientific staff and leadership from Focal will join Continuity, further enhancing its internal capabilities. A dedicated research and development facility in Cary, NC that supports ongoing platform and pipeline advancement is also part of the acquisition and will be expanded to support other delivery platforms. Visionary Founders Driving the Innovation Focal Medical was co-founded by: Jen Jen Yeh , MD , a surgical oncologist and professor at UNC-Chapel Hill with joint appointments in Surgery and Pharmacology. She serves as assistant dean of translational research in UNC School of Medicine and associate director of translational research in UNC Lineberger Comprehensive Cancer Center. Dr. Yeh is widely recognized for her expertise in pancreatic cancer and translational oncology. Joseph DeSimone , PhD , an award-winning chemist, entrepreneur, and academic, currently serving as the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University . He is globally known for his breakthroughs in materials science, nanomedicine, and advanced manufacturing, including 3D printing. Their iontophoresis system is designed to deliver gemcitabine, an FDA-approved chemotherapy agent, directly into pancreatic tumors. Traditional systemic administration of gemcitabine is often limited by poor tumor penetration and significant toxicity. Focal's approach bypasses those limitations by delivering the drug directly to the tumor site with high precision and minimal systemic toxicity. "After nearly a decade of R&D, we are excited to join the Continuity Biosciences family," said Tony Voiers , Acting CEO of Focal Medical. "We are grateful to our founders, scientific collaborators, and investors who have helped us reach this pivotal point. Partnering with Continuity ensures that this novel therapy moves forward into the clinic where it has the potential to help patients facing one of the deadliest cancers." This acquisition reinforces Continuity Biosciences' commitment to building a diverse portfolio of clinically meaningful drug delivery platforms and signals a decisive move toward becoming a clinical-stage leader in site-specific therapy. About Continuity Biosciences Continuity Biosciences, LLC is a biopharmaceutical company developing advanced drug delivery technologies that address the limitations of conventional therapeutic administration. With operations in Bradenton, FL ; Houston, TXRaleigh, NC ; and Torino, Italy , the company focuses on combination drug-device platforms for chronic and complex conditions. Visit:
Globe and Mail
2 hours ago
- Globe and Mail
Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development
LAS VEGAS , June 4, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera. Ainnova's new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company's Vision AI software platform, which then produces a "risk report" in mere seconds. Vinicio Vargas , Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, "The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market. "Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists. Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach." Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD). Currently, Ainnova's Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera. Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova's technology portfolio. AAC owns the global licensing rights to develop, maintain, and market Ainnova's technology portfolio. About Ainnova Tech, Inc. Ainnova is a Nevada -based healthtech startup with headquarters in San Jose, Costa Rica , and Houston, Texas . Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: - technologies - ai Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
National Post
2 hours ago
- National Post
LevelBlue Report Reveals Increasing Risks To Healthcare Organizations Are Driving Cyber Resilience
Article content LevelBlue finds that only 29% of healthcare executives say they are prepared for AI-powered threats. Article content DALLAS — LevelBlue, a leading provider of managed security services, strategic consulting, and threat intelligence, today released its 2025 Spotlight Report: Cyber Resilience and Business Impact in Healthcare. The findings reveal how the healthcare industry is protecting itself from increasingly numerous sophisticated attacks. Article content The new report found that 32% of healthcare executives say their organization suffered a breach in the past 12 months, and nearly half (46%) say they are experiencing a significantly higher volume of attacks. As artificial intelligence (AI) promises healthcare organizations unprecedented levels of efficiency, optimized processes, and enhanced automation, the report reveals that only 29% of healthcare executives say they are prepared for AI-powered threats despite 41% believing they will happen. Article content At the same time, the software supply chain remains a blind spot, with only a small portion of executives recognizing the associated risks. 54% say they have very low to moderate visibility into the software supply chain, and only 21% say they are investing significantly in software supply chain security. Article content However, cyber resilience measures are becoming more integral to business operations, with 61% of healthcare organizations now aligning their cybersecurity teams with lines of business, a sign that resilience is increasingly seen as a shared responsibility across departments. Moreover, nearly half (44%) expect to enlist managed security service providers (MSSPs) in the next two years to help them manage the increasingly complex and dynamic threat landscape, an increase from 30% that have done so over the past 12 months. Additionally, 59% of leadership roles are measured against cybersecurity KPIs, and nearly half (43%) say they allocate cybersecurity budgets at the outset of new initiatives – a critical step toward embedding security into innovation efforts. Article content 'With the rising risk of AI-powered cyberattacks and vulnerabilities in the software supply chain, achieving cyber resilience in healthcare is more critical than ever,' said Theresa Lanowitz, Chief Evangelist of LevelBlue. 'Our research shows that healthcare organizations are no longer viewing cybersecurity as just an IT issue; it's now a business priority. Still, there is work to be done to properly prepare and protect themselves.' Article content Healthcare organizations are making progress in integrating cybersecurity across their operations, but there is still work to be done. When asked to what extent their organization is investing in certain measures to prepare for new and emerging types of cyber threats, healthcare executives say they are most likely to invest significantly in: Article content Based on these findings, LevelBlue recommends four specific steps to achieve cyber resilience, regardless of the industry: Push cyber resilience up the organization, embed cybersecurity responsibilities throughout the organization, be proactive (not reactive), and prioritize resilience in the software supply chain. Article content Download the complete findings of the 2025 LevelBlue Spotlight Report: Cyber Resilience and Business Impact in Healthcare at this link here to learn how healthcare organizations are adapting to the changing threat landscape. This report follows the April 2025 release of the 2025 LevelBlue Futures Report: Cyber Resilience and Business Impact, which can be found here. Article content For more information on LevelBlue and its managed security, consulting, and threat intelligence services, please visit Methodology The research is based on a quantitative survey that was carried out by FT Longitude in January 2025. There were a total of 1,500 C-suite and senior executives surveyed across 14 countries and seven industries: energy and utilities, financial services, healthcare, manufacturing, retail, transportation, and US SLED (state, local government, and higher education). To be counted as a cyber resilient organization, respondents must have met the qualifications listed under 'Five Characteristics of a Cyber Resilient Organization.' The total number surveyed in healthcare is 220. Article content About LevelBlue Article content We simplify cybersecurity through award-winning managed services, experienced strategic consulting, threat intelligence, and renowned research. Our team is a seamless extension of yours, providing transparency and visibility into security posture and continuously working to strengthen it. Article content We harness security data from numerous sources and enrich it with artificial intelligence to deliver real-time threat intelligence- this enables more accurate and precise decision making. With a large, always-on global presence, LevelBlue sets the standard for cybersecurity today and tomorrow. We easily and effectively manage risks so you can focus on your business. Article content Article content Article content Article content Contacts Article content Media Contact Article content Article content Jessica Bettencourt Article content Article content Article content
